Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or ...

While presenting the data at this year's American Society of Clinical Oncology (ASCO) annual meeting, Peter Voorhees, MD, of ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd ...

DelveInsight's Anti-CD38 mAb Market Insights report includes a comprehensive understanding of current treatment practices, emerging anti-CD38 mAb, market share of individual therapies, and current ...

Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a ...

What this really studied was the addition of an anti-CD38 antibody to this triplet. We have some other clinical trials as well that just have the anti-CD38 antibody with lenalidomide and ...

Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM not ...

The team confirmed that the addition of an anti-CD38 monoclonal antibody to a triplet consisting of a PI with an IMiD ...

Anti-CD38 antibodies (help the immune system kill cancer cells) Your health care provider will review your medical history and decide if Tecvayli is right for you. ...

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant . Approval based on positive results from the IMROZ phase 3 ...

Paris: Sanofi has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...